Under construction – not a live service
Sign in
Taking people in ChinaNo phase

Imaging scan to find thyroid cancer that returns or spreads after surgery

Studies a 68Ga-FAPI PET/CT scan in adults with thyroid cancer after surgery.

Plain-language title generated from the registry record
Registry title: The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

Key facts

Where
Shanghai, ChinaSee the site

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Source: NCT06800768, who can take part

Where in China

  • Ruijin Hospital affiliated to Shanghai Jiao Tong University of MedicineShanghai, ChinaTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
Ruijin Hospital
Trial code
NCT06800768
Record updated
30 January 2025
Original description
This study aims to investigate the value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery.Read full original descriptionShow less

The Value of 68Ga-FAPI PET/CT in Detecting Recurrent and Metastatic Lesions in Patients with Thyroid Cancer After Surgery

This study aims to investigate the value of 68Ga-FAPI PET/CT in detecting recurrent and metastatic lesions in patients with thyroid cancer after surgery.

Inclusion: Patients with thyroid cancer who have undergone surgery and are suspected of recurrence or metastasis during clinical evaluation; Signed and dated informed consent form; Commitment to comply with research procedures and co-operation in the implementation of the full research process; Aged 18-80 years old.

Exclusion: Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc; Intestinal perforation, complete intestinal obstruction; Pregnant women and women who may be pregnant, women who are breastfeeding; Non-compliant person.

ClinicalTrials.gov NCT06800768